| Literature DB >> 31569378 |
Tomáš Zárybnický1, Petra Matoušková2, Martin Ambrož3, Zdeněk Šubrt4,5, Lenka Skálová6, Iva Boušová7.
Abstract
The selection of a suitable combination of reference genes (RGs) for data normalization is a crucial step for obtaining reliable and reproducible results from transcriptional response analysis using a reverse transcription-quantitative polymerase chain reaction. This is especially so if a three-dimensional multicellular model prepared from liver tissues originating from biologically diverse human individuals is used. The mRNA and miRNA RGs stability were studied in thirty-five human liver tissue samples and twelve precision-cut human liver slices (PCLS) treated for 24 h with dimethyl sulfoxide (controls) and PCLS treated with β-naphthoflavone (10 µM) or rifampicin (10 µM) as cytochrome P450 (CYP) inducers. Validation of RGs was performed by an expression analysis of CYP3A4 and CYP1A2 on rifampicin and β-naphthoflavone induction, respectively. Regarding mRNA, the best combination of RGs for the controls was YWHAZ and B2M, while YWHAZ and ACTB were selected for the liver samples and treated PCLS. Stability of all candidate miRNA RGs was comparable or better than that of generally used short non-coding RNA U6. The best combination for the control PCLS was miR-16-5p and miR-152-3p, in contrast to the miR-16-5b and miR-23b-3p selected for the treated PCLS. Our results showed that the candidate RGs were rather stable, especially for miRNA in human PCLS.Entities:
Keywords: RT-qPCR; human liver; mRNA; miRNA; precision-cut liver slices; reference gene
Mesh:
Substances:
Year: 2019 PMID: 31569378 PMCID: PMC6826422 DOI: 10.3390/genes10100763
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Summary of human samples.
| Human Sample | Gender (Age) | Reason of Surgery | Long-Term Pharmacotherapy | PCLS Preparation |
|---|---|---|---|---|
| L1 | Female | CRC 1 | Insulin | No |
| L3 | Male | CCC 2 | Allopurinol, felodipine, ramipril, indapamide, atorvastatin, citalopram, pregabalin | No |
| L4 | Male | Adenoma | Mesalazine, omeprazole, escitalopram, budesonide | No |
| L5 | Male | CRC | Ramipril, atorvastatin, metformin, allopurinol | Yes |
| L6 | Male | CRC | Hydrochlorothiazide | Yes |
| L7 | Male | CRC | Nitrendipine, acetylsalicylic acid | Yes |
| L8 | Female | CRC | Verapamil, trandolapril | No |
| L9 | Male | CRC | Betaxolol | Yes |
| L10 | Female | HCC 3 | Pantoprazole | No |
| L11 | Female | CRC, liver metastases | None | Yes |
| L12 | Female | CRC | Lerkanidipine, furosemide, perindopril, nadroparin | No |
| L13 | Female | CCC | Nadroparin | No |
| L14 | Female | BFNH 4 | None | Yes |
| L15 | Female | CRC | Nebivolol, simvastatin, digoxin, irbesartan, hydrochlorothiazide, nadroparin | No |
| L16 | Female | CRC | None | Yes |
| L17 | Male | CRC | None | No |
| L18 | Male | HCC | Lacidipine, solifenacin, tamsulosin | No |
| L19 | Female | CRC | Amlodipine | No |
| L20 | Female | Abscess | None | No |
| L21 | Male | Jejunal adenocarcinoma | None | No |
| L22 | Female | CRC | Telmisartan, nitrendipine, formoterol | No |
| L23 | Male | CRC | Furosemide, amlodipine, acetylsalicylic acid, telmisartan, salmeterol, fluticasone | No |
| L24 | Male | HCC | Metoprolol, felodipin, ramipril, metformin, gliclazid, finasteride, warfarin,nadroparin | No |
| L25 | Male | CRC | Perindopril, betaxolol, metformin, atorvastatin, allopurinol, insulin | No |
| L26 | Male | CRC | None | No |
| L27 | Male | CRC | Insulin, atorvastatin | No |
| L28 | Female | BFNH | None | Yes |
| L29 | Male | Renal cell carcinoma, liver metastases | None | No |
| L30 | Female | CRC, liver metastases | Hydrochlorothiazide, betaxolol, acetylsalicylic acid, zolpidem, insulin | Yes |
| L33 | Female | CCC | Lerkanidipine, irbesartan, hydrochlorothiazide, lansoprazole, levothyroxine, acetylsalicylic acid, fenofibrate, nebivolol | No |
| L34 | Male | CRC | Ramipril, felodipine, metoprolol, rosuvastatin, acetylsalicylic acid | No |
| L35 | Male | CRC, liver metastases | Tamsulosin, metoprolol, omeprazole | No |
| L36 | Female | CCC | Simvastatin, bisoprolol, furosemide, ramipril, enoxaparin, zolpidem | Yes |
| L37 | Male | Neuroendocrine tumor, liver metastases | Insulin | Yes |
| L38 | Male | CCC | None | Yes |
1 CRC, colorectal carcinoma; 2 CCC, cholangiocellular carcinoma; 3 HCC, hepatocellular carcinoma; 4 BFNH, benign focal nodular hyperplasia.
Description of selected candidate reference genes and genes of interest.
| Gene Symbol | Gene Name | GeneBank or miRbase Accession Number | Gene Function | Primer Sequences 5´-3´ | Tm1 (°C) | E2 (%) |
|---|---|---|---|---|---|---|
|
| ||||||
|
| Actin beta | NM_001101.4 | Structural protein of cytoskeleton | F3: TCCCTGGAGAAGAGCTACGAG | 86.5 | 102 |
|
| Beta-2-microglobulin | NM_004048.2 | Beta-chain of major histocompatibility complex | F: TGCTGTCTCCATGTTTGATGTATC | 83 | 99 |
|
| Glyceraldehyde-3-phosphate dehydrogenase | NM_002046 | Enzyme of glycolysis pathway | F: GAGTCCACTGGCGTCTTCAC | 86 | 101 |
|
| Hypoxanthine phosphoribosyltransferase 1 | NM_000194.2 | Metabolism of purines | F: TGGTCAGGCAGTATAATCCAAAGA | 82 | 101 |
|
| Succinate dehydrogenase complex, subunit A | NM_004168.3 | Critical function in mitochondrial respiratory chain | F: TGGGAACAAGAGGGCATCTG | 79.5 | 99 |
|
| Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta | NM_003406.3 | Important protein for many signal transduction pathways | F: TGATCCCCAATGCTTCACAAG | 77.5 | 102 |
|
| ||||||
| miR-16-5p | MicroRNA 16 (5p) | MIMAT0000069 | Regulation of apoptosis | RT5: GTCTCCTCTGGTGCAGGGTCCGAG GTATTCGCACCAGAGGAGACCGCC AA | 79 | 102 |
| miR-23b-3p | MicroRNA 23b (3p) | MIMAT0000418 | Associated with cell proliferation, invasion, and apoptosis | RT: GTCTCCTCTGGTGCAGGGTCCGAGGTA TTCGCACCAGAGGAGACGTGGTA | 77.5 | 109 |
| miR-93-5p | MicroRNA 93 (5p) | MIMAT0000093 | OncomiR, plays an essential role in tumorigenesis and progression of various carcinomas | RT: GTCTCCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGGAGAC | 78.5 | 105 |
| miR-152-3p | MicroRNA 152 (3p) | MIMAT0000438 | Regulates hepatic glycogenesis, tumor suppressor | RT: GTCTCCTCTGGTGCAGGGTCCGAGGTA TTCGCACCAGAGGAGACCCAAGT | 78.5 | 100 |
| U6 | Small nuclear RNA U6 | NR_003027 | RNA splicing | R: AACGCTTCACGAATTTGCGTG | 80.5 | 99 |
| universal | R: GAGGTATTCGCACCAGAGGA | |||||
|
| ||||||
| CYP1A2 | Cytochrome P450 family 1 subfamily A member 2 | NM_000761 | Phase I biotransformation | F: CTTCCCTGAGAGTAGCGATGAGA | 85.5 | 101 |
| CYP3A4 | Cytochrome P450 family 3 subfamily A member 4 | NM_017460.5 | Phase I biotransformation | F: CCCCTGAAATTAAGCTTAGGAGG | 82.5 | 99 |
| miR-27a-3p | MicroRNA 27a (3p) | MIMAT0000084 | Direct regulation of CYP3A4 | RT: GTCTCCTCTGGTGCAGGGTCCGAGGTA TTCGCACCAGAGGAGACGCGGAA | 80.5 | 106 |
| miR-203a-3p | MicroRNA 203a (3p) | MIMAT0000264 | Indirect regulation of CYP1A2 via PXR receptor | RT: GTCTCCTCTGGTGCAGGGTCCGAGGTA TTCGCACCAGAGGAGACCTAGTG | 78.5 | 105 |
1 Tm, melting temperature; 2 E, assays efficiency; 3 F, forward primer; 4 R, reverse primer; 5 RT, reverse transcription primer.
Figure 1Analysis of candidate reference genes for mRNA normalization in human liver. (A) Boxplot of quantification cycle (Cq) values for each RG in all liver samples (n = 35). The box indicates the 25% and 75% percentiles, whiskers represent the maximum and minimum values and the median is depicted by the line across the box; (B) Comprehensive stability values of RGs according to RefFinder; (C) Determination of the optimal number of reference genes (RGs) by geNorm analysis; (D, E) Effects of different normalization approaches on the expression of CYP1A2 (D) and CYP3A4 (E).
Figure 2Viability results of human precision-cut liver slices (PCLS) during 24-h incubation. (A) adenosine triphosphate content; (B) lactate dehydrogenase leakage. Results are presented as mean ± SD (n = 3).
Figure 3Analysis of candidate reference genes for mRNA normalization in human PCLS. (A) Comprehensive stability values of RGs in PCLS incubated for 24 h with dimethyl sulfoxide (DMSO) according to RefFinder. Genes are presented on the X-axis in the order of decreasing stability; (B) RefFinder ranking of RGs with individual values in PCLS incubated for 24 h with DMSO (controls); and (C) Comprehensive stability values of RGs in PCLS incubated for 24 h with cytochrome P450 (CYP) inducers (treated groups) according to RefFinder. Genes are presented on the X-axis in the order of decreasing stability; (D) RefFinder ranking of RGs with individual values in PCLS incubated for 24 h with CYP inducers (treated groups).
Figure 4RefFinder ranking of RGs with individual values in PCLS within 24-h incubation in the control (A) and treated group (B); (C) Effects of different reference genes on the normalization of CYP3A4 expression in sample L28. Results are presented as mean ± SD (n = 3); (D,E) Relative mRNA expression of CYP3A4 (D) and CYP1A2 (E) under the effect of rifampicin (RIF) 10 µM and β-naphthoflavone (BNF) 10 µM, normalized to geometric mean of YWHAZ and B2M. Results are presented as mean ± SD (n = 3).
Figure 5RefFinder ranking of miRNA RGs with individual values in PCLS within 24-h incubation in the control (A) and treated group (B). Relative miR-27a-3p and miR-203a-3p expression under the effect of RIF 10 µM (C) and BNF 10 µM (D), respectively, normalized to a geometric mean of miR-16-5p and miR-23b-3p. Results are presented as mean ± SD (n = 3).